Harbinger Health Targets High-Mortality Cancers First With AI-Driven MCED Platform

Harbinger Is Laying Groundwork For Population-Wide Screening With Modular, Methylation-Based Testing

 
• By Shubham Singh
The Cambridge, MA-based company presented two late-breaking abstracts at the American Association for Cancer Research (AACR) Annual Meeting on 29 April.

More from Oncology

More from Medtech Insight